SCHEMBL2277187

SCHEMBL2277187

Cc1cc(O)c(C(=O)C=Cc2cccc(NC(=O)OC(C)(C)C)c2)c(=O)n1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
ABCB1 P08183 2/20 0.42
MMP1 P03956 4/20 0.40
MMP2 P08253 4/20 0.40
MMP9 P14780 4/20 0.40
ABCG2 Q9UNQ0 1/20 0.38
CYP2C9 P11712 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
USP2 O75604 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
RECQL P46063 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2277182 1.00 HDAC3 (0.50) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL2275832 0.84 NPC1 (0.50) NPC1RAB9AABCB1MMP1MMP2
SCHEMBL2275829 0.84 NPC1 (0.50) NPC1RAB9AABCB1MMP1MMP2
SCHEMBL2280461 0.84 RAB9A (0.48) HDAC3HDAC1HDAC2HDAC6NPC1
SCHEMBL2280459 0.84 RAB9A (0.48) HDAC3HDAC1HDAC2HDAC6NPC1
SCHEMBL2279274 0.83 NPC1 (0.48) NPC1RAB9AMMP1MMP2MMP9
SCHEMBL12374658 0.83 NPC1 (0.48) NPC1RAB9AMMP1MMP2MMP9
SCHEMBL2285362 0.81 CA12 (0.41) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL2281390 0.81 MAOA (0.51) NPC1RAB9AABCB1ABCG2CYP2C9
SCHEMBL2281391 0.81 MAOA (0.51) NPC1RAB9AABCB1ABCG2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 HDAC3 1688/4885HDAC1 1097/4885HDAC2 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.